Skip to main content
Clinical Trials/NCT06904664
NCT06904664Not yet recruitingNot Applicable

Individualized Temperature Health Risk Early Warning and Risk Factor Management App for Reducing the Recurrence Risk of Stroke: A Multicenter, Randomized Controlled Trial Study

Xuanwu Hospital, Beijing0 sites10,184 target enrollmentStarted: September 1, 2025Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Status
Not yet recruiting
Enrollment
10,184
Primary Endpoint
1-year recurrence rate of stroke

Study Overview

Brief Summary

This study employs individualized temperature health risk early warning and risk factor management interventions for stroke, and explores their actual intervention effects. This enables patients to promptly understand their own risk levels and take corresponding protective measures, thereby enhancing the management outcomes and quality of life. The study also promotes the interdisciplinary integration of environmental epidemiology and clinical intervention management, providing new ideas and methodological support for future relevant research.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Other
Masking
None

Eligibility Criteria

Ages
40 Years to 80 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Aged 40 to 80, with no gender restrictions;
  • •Acute ischemic stroke inpatients within 2 weeks of onset, where the onset time is the time when stroke symptoms appear or the last known normal time of the patient (when it is an onset during sleep or the symptom onset time cannot be accurately obtained due to aphasia, impaired consciousness, etc.); ③ Confirmed diagnosis of ischemic stroke by CT or MRI of the brain within 2 weeks after symptom onset;
  • •Local residents (residing for ≥6 months); ⑤ Patients who voluntarily participate in the study, have high compliance, and can sign the informed consent form;
  • •Patients who own a smartphone or other smart devices.

Exclusion Criteria

  • •Patients diagnosed with other cerebrovascular diseases (hemorrhagic stroke, transient ischemic attack, cerebral venous sinus thrombosis, etc.) or non-cerebrovascular diseases;
  • •Known pregnant or lactating women, or those who tested positive on a pregnancy test before cluster randomization;
  • •Patients with other conditions that may affect participation in the trial (e.g., refractory hypertension, severe aphasia, etc.);
  • •Patients undergoing psychiatric/psychological treatment that may contaminate the results; ⑤ Patients with a life expectancy of less than one year (e.g., coexisting malignant tumors, severe cardiopulmonary diseases, etc.); ⑥ Patients already participating in other interventional clinical studies that may influence the outcome assessment; ⑦ Patients for whom the investigator deems unsuitable for participation in this study or who may pose significant risks to the patients (e.g., cognitive impairment preventing understanding and/or compliance with the study procedures and/or follow-up).

Arms & Interventions

Temperature health risk early warning group

Experimental

Receive individualized temperature health risk warning through the application

Intervention: Temperature health risk early warning (Other)

Risk factor management group

Experimental

Receive individualized prevention risk factor management information for stroke through the application

Intervention: Risk factor management (Other)

Enhanced intervention group

Experimental

Receive individualized temperature health risk warning and prevention risk factor management information for stroke through the application

Intervention: Individualized temperature health risk early warning and risk factor management (Other)

Routine education group

No Intervention

Only receive routine health education, without receiving individualized temperature health risk warning or prevention risk factor management information for stroke through the application

Outcomes

Primary Outcomes

1-year recurrence rate of stroke

Time Frame: Intervention at the 1-year

Secondary Outcomes

  • 3-month, 6-month, 9-month recurrence rate of stroke(Intervention at 3-month, 6-month, 9-month)
  • Cardiovascular system function indicators(Baseline; Intervention at 3-month, 6-month, 9-month and 1-year)
  • Laboratory examination(Baseline; Intervention at 3-month, 6-month, 9-month and 1-year)
  • Modified Rankin Scale(Baseline; Intervention at 3-month, 6-month, 9-month and 1-year)
  • European five-dimensional five-level Health Scale score(Baseline; Intervention at 3-month, 6-month, 9-month and 1-year)
  • Risk perception scale of stroke recurrence(Baseline; Intervention at 3-month, 6-month, 9-month and 1-year)
  • Environmental temperature health risk perception assessment 1uestionnaire(Baseline; Intervention at 3-month, 6-month, 9-month and 1-year)
  • Stroke health literacy score(Baseline; Intervention at 3-month, 6-month, 9-month and 1-year)
  • Health status score(Baseline; Intervention at 3-month, 6-month, 9-month and 1-year)
  • System usability scale(Intervention at 3-month, 6-month, 9-month and 1-year)

Investigators

Sponsor Class
Other
Responsible Party
Sponsor

Similar Trials